BRCA1 and neoplasm: For HGSOC, large, randomized trials with ICB alone or combined with first-line standard chemotherapy and/or bevacizumab have demonstrated minimal clinical benefit across molecularly selected patient sub-groups (germline or somatic BRCA1/2 mutations, HRD, PD-L1 status, or high tumor mutational burden) [112–114].